Business
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partners
About this update from Senti Biosciences Holdings, Inc.
[{"type":"image","alt":"Senti Biosciences, Inc.","displaySize":"","headline":null,"caption":"Senti Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/4576ff302df7a498c5620f46e0596daf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LwHg6RoZ4drUhxxgTNKbZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4576ff302df7a498c5620f46e0596daf","width":166,"height":42}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET.","length":695,"tagName":"p"},{"type":"text","content":"Live audio of the webcast will be available on the Events page of the Investors section of the Company’s website (sentibio.com).","length":128,"tagName":"p"},{"type":"text","content":"Interested parties may access the live video webcast here.","length":58,"tagName":"p"},{"type":"text","content":"About Senti Bio","length":15,"tagName":"p"},{"type":"text","content":"Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti B...